Skip to Content

HPV Vaccine Generally Well Tolerated in Males

WEDNESDAY, Nov. 4, 2020 -- Human papillomavirus (HPV) vaccines are safe and well tolerated in males, with few reports of adverse events, according to a study published online Nov. 3 in the British Journal of Clinical Pharmacology.

Giulia Bonaldo, from the University of Bologna in Italy, and colleagues reviewed all reports of adverse events following immunization (AEFI) present in the U.S. Vaccine Adverse Event Reporting System from Jan. 1, 2006, to Sept. 30, 2018, to update knowledge on the safety profiles of HPV vaccines in the male population.

The researchers retrieved 5,493 reports of AEFI. The events most often reported and that occurred more often with HPV versus other vaccines in males were syncope, loss of consciousness, and fall (701, 425, and 272 events; reporting odds ratios, 2.85, 2.79, and 3.54, respectively).

"Our analysis shows that HPV vaccines are safe and well tolerated in the male population," the authors write. "Between 2006 and 2017, 111,677,552 doses of HPV vaccines were distributed in the USA. Considering the number of reports retrieved in our analysis (5,493), we calculated a reporting rate of 4.92 reports per 100,000 doses."

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Timing, Intensity of Oral Sex Are Risk Factors for HPV-OPC

MONDAY, Jan. 11, 2021 -- In addition to number of oral sex partners, timing and intensity of oral sex are independent risk factors for human papillomavirus-related oropharyngeal...

Interventions to Increase HPV Vaccine Coverage Cost-Effective

MONDAY, Nov. 16, 2020 -- Three interventions for increased human papillomavirus (HPV) vaccine coverage are cost-effective, according to a study published online Nov. 16 in...

HPV Vaccination Tied to Decrease in Invasive Cervical Cancer Risk

THURSDAY, Oct. 1, 2020 -- Quadrivalent human papillomavirus (HPV) vaccination of girls and women aged 10 to 30 years is associated with a reduced risk for invasive cervical...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.